文献速递骨质疏松与钙磷/甲状旁腺

维生素D在COVID-19中的预后和治疗作用:系统综述与Meta分析

Prognostic and Therapeutic Role of Vitamin D in COVID-19: Systematic Review and Meta-analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该系统综述与Meta分析检索截至2021年5月30日的观察性研究和随机对照试验,纳入76项研究,其中72项观察性研究(n=1,976,099)进行Meta分析。维生素D缺乏/不足增加COVID-19易感性(OR 1.46)、重症(OR 1.90)和死亡(OR 2.07)的比值比,但偏倚风险高、异质性大;4项随机对照试验异质性大无法合并。

要点

  • 维生素D缺乏/不足与COVID-19易感性增加相关(OR 1.46;95%CI 1.28-1.65)。
  • 维生素D缺乏/不足与重症COVID-19(OR 1.90)和死亡(OR 2.07)相关,但死亡关联在排除高偏倚风险研究后不显著。
  • 4项随机对照试验异质性大,无法进行Meta分析。

核心结论

  • 与死亡率的关联较不稳健。
  • 随机对照试验异质性大,无法进行Meta分析。

研究设计与样本

  • 系统综述与Meta分析,检索CINAHL、Cochrane图书馆、EMBASE、PubMED、Scopus和Web of Science截至2021年5月30日。
  • 纳入76项符合标准的研究,其中72项观察性研究(n=1,976,099)纳入Meta分析。
  • 观察性研究使用纽卡斯尔-渥太华量表评估偏倚风险,随机对照试验使用AUB-KQ1 Cochrane工具。

主要发现

  • 维生素D缺乏/不足增加COVID-19发病的比值比(OR 1.46;95%CI 1.28-1.65;P<0.0001;I²=92%)。
  • 维生素D缺乏/不足增加重症疾病的比值比(OR 1.90;95%CI 1.52-2.38;P<0.0001;I²=81%)。
  • 维生素D缺乏/不足增加死亡的比值比(OR 2.07;95%CI 1.28-3.35;P=0.003;I²=73%)。
  • COVID-19患者25-羟基维生素D浓度低于对照(平均差-3.85 ng/mL;95%CI -5.44至-2.26;P≤0.0001)。
  • 重症COVID-19患者25-羟基维生素D浓度低于非重症对照(平均差-4.84 ng/mL;95%CI -7.32至-2.35;P=0.0001),死亡者低于存活者(平均差-4.80 ng/mL;95%CI -7.89至-1.71;P=0.002)。

关键数值与推荐

  • 维生素D缺乏/不足与死亡的关联在排除高偏倚风险研究或未校正效应估计研究后不显著。
  • 所有分析中偏倚风险和异质性均高。
  • 维生素D检测时机、重症COVID-19定义和维生素D缺乏/不足定义的差异部分解释了异质性。
  • 4项随机对照试验异质性大,无法进行Meta分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有分析中偏倚风险和异质性均高。
  • 维生素D缺乏/不足与死亡的关联在排除高偏倚风险研究或未校正效应估计研究后不显著。
  • 维生素D检测时机、重症COVID-19定义和维生素D缺乏/不足定义的差异部分解释了异质性。
  • 4项随机对照试验异质性大,无法进行Meta分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Vitamin D deficiency/insufficiency may increase the susceptibility to coronavirus disease 2019 (COVID-19). We aimed to determine the association between vitamin D deficiency/insufficiency and susceptibility to COVID-19, its severity, mortality, and role of vitamin D in its treatment. METHODS: We searched CINAHL, Cochrane library, EMBASE, PubMED, Scopus, and Web of Science up to May 30, 2021, for observational studies on association between vitamin D deficiency/insufficiency and susceptibility to COVID-19, severe disease, and death among adults, and, randomized controlled trials (RCTs) comparing vitamin D treatment against standard care or placebo, in improving severity or mortality among adults with COVID-19. Risk of bias was assessed using Newcastle-Ottawa scale for observational studies and AUB-KQ1 Cochrane tool for RCTs. Study-level data were analyzed using RevMan 5.3 and R (v4.1.0). Heterogeneity was determined by I2 and sources were explored through prespecified sensitivity analyses, subgroup analyses, and meta-regressions. RESULTS: Of 1877 search results, 76 studies satisfying eligibility criteria were included. Seventy-two observational studies were included in the meta-analysis (n = 1 976 099). Vitamin D deficiency/insufficiency increased the odds of developing COVID-19 (odds ratio [OR] 1.46; 95% CI, 1.28-1.65; P < 0.0001; I2 = 92%), severe disease (OR 1.90; 95% CI, 1.52-2.38; P < 0.0001; I2 = 81%), and death (OR 2.07; 95% CI, 1.28-3.35; P = 0.003; I2 = 73%). The 25-hydroxy vitamin D concentrations were lower in individuals with COVID-19 compared with controls (mean difference [MD] -3.85 ng/mL; 95% CI, -5.44 to -2.26; P ≤ 0.0001), in patients with severe COVID-19 compared with controls with nonsevere COVID-19 (MD -4.84 ng/mL; 95% CI, -7.32 to -2.35; P = 0.0001) and in nonsurvivors compared with survivors (MD -4.80 ng/mL; 95% CI, -7.89 to -1.71; P = 0.002). The association between vitamin D deficiency/insufficiency and death was insignificant when studies with high risk of bias or studies reporting unadjusted effect estimates were excluded. Risk of bias and heterogeneity were high across all analyses. Discrepancies in timing of vitamin D testing, definitions of severe COVID-19, and vitamin D deficiency/insufficiency partly explained the heterogeneity. Four RCTs were widely heterogeneous precluding meta-analysis. CONCLUSION: Multiple observational studies involving nearly 2 million adults suggest vitamin D deficiency/insufficiency increases susceptibility to COVID-19 and severe COVID-19, although with a high risk of bias and heterogeneity. Association with mortality was less robust. Heterogeneity in RCTs precluded their meta-analysis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Dissanayake HA, de Silva NL, Sumanatilleke M, et al. Prognostic and Therapeutic Role of Vitamin D in COVID-19: Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2022. PMID: 34894254. doi:10.1210/clinem/dgab892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。